Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: UTR024
MIFTS: 58

Uterine Carcinosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Uterine Carcinosarcoma

About this section

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 12 20 58 54 6 15 17 70
Carcinosarcoma of the Corpus Uteri 20 58
Malignant Mixed Müllerian Tumor of the Corpus Uteri 20
Malignant Mixed Mullerian Tumor of the Corpus Uteri 58
Malignant Mixed Müllerian Tumor of Corpus Uteri 20
Mixed Müllerian Cancer of Corpus Uteri 20
Mixed Mullerian Cancer of Corpus Uteri 58
Mixed Mullerian Sarcoma of Uterus 12
Uterine Corpus Carcinosarcoma 70

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:6171
NCIt 50 C42700
SNOMED-CT 67 702369008
ICD10 via Orphanet 33 C54.9
Orphanet 58 ORPHA213610
UMLS 70 C0280630 C1704376
Sources

Summaries for Uterine Carcinosarcoma

About this section
GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 213610 Definition Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.

MalaCards based summary : Uterine Carcinosarcoma, also known as carcinosarcoma of the corpus uteri, is related to carcinosarcoma and endometrial stromal sarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include breast, uterus and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Sources

Related Diseases for Uterine Carcinosarcoma

About this section

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 396)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 30.9 TP53 PTEN PPP2R1A POLE PIK3CA PGR
2 endometrial stromal sarcoma 30.7 U2AF1 TP53 PGR KIT
3 sarcoma 30.6 TP53 PTGS2 PIK3CA KIT HRAS CTNNB1
4 fallopian tube carcinoma 30.3 TP53 PTEN PGR ERBB2
5 large cell neuroendocrine carcinoma 30.2 KIT ERBB2 EGFR
6 adenosarcoma 30.2 TP53 PGR KIT ERBB2
7 cervical squamous cell carcinoma 30.2 TP53 PIK3CA EGFR CTNNB1
8 lynch syndrome 30.2 TP53 PTEN POLE PIK3CA HRAS EGFR
9 endometrial serous adenocarcinoma 30.2 TP53 PTEN PPP2R1A POLE PIK3CA PGR
10 myoma 30.1 TP53 PGR KIT EGFR
11 wilms tumor 1 29.9 U2AF1 TP53 PGR FBXW7 ERBB2 CTNNB1
12 endometrial adenocarcinoma 29.9 TP53 PTEN PGR FGFR2 ERBB2 EGFR
13 rhabdomyosarcoma 29.9 TP53 SNAI2 PTEN PIK3CA LRRC56 KIT
14 myelodysplastic syndrome 29.8 U2AF1 TP53 PTEN LRRC56 KIT HRAS
15 endometrial cancer 29.5 TP53 PTGS2 PTEN PPP2R1A POLE PIK3R1
16 cervical cancer 29.5 U2AF1 TP53 PTGS2 PTEN PIK3CA LRRC56
17 serous cystadenocarcinoma 29.5 TP53 PTEN PPP2R1A POLE PIK3CA PGR
18 peripheral nervous system disease 29.4 U2AF1 TP53 PTGS2 PTEN KIT HRAS
19 adenocarcinoma 29.3 TP53 PTGS2 PTEN POLE PIK3CA KIT
20 squamous cell carcinoma 29.1 U2AF1 TP53 PTGS2 PTEN PIK3CA HRAS
21 thyroid hurthle cell adenoma 10.5 PTEN PIK3CA
22 ovarian clear cell adenofibroma 10.5 PTEN PIK3CA
23 clear cell adenofibroma 10.5 PPP2R1A PIK3CA
24 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
25 pancreatic signet ring cell adenocarcinoma 10.4 TP53 HRAS
26 breast duct papilloma 10.4 PTEN PGR
27 bartholin's gland adenoma 10.4 TP53 PGR
28 bartholin's gland benign neoplasm 10.4 TP53 PGR
29 vestibular gland benign neoplasm 10.4 TP53 PGR
30 parameningeal embryonal rhabdomyosarcoma 10.4 TP53 PIK3CA FBXW7
31 glassy cell carcinoma of the cervix 10.4 PGR ERBB2
32 breast intraductal papillomatosis 10.4 PGR ERBB2
33 nipple carcinoma 10.4 PGR ERBB2
34 myoepithelial carcinoma 10.4 TP53 PIK3CA HRAS
35 vulvar intraepithelial neoplasia 10.4 TP53 CTNNB1
36 ovarian carcinosarcoma 10.4 TP53 PIK3CA ERBB2
37 breast squamous cell carcinoma 10.4 TP53 ERBB2
38 anal squamous cell carcinoma 10.4 TP53 PIK3CA FBXW7
39 basaloid lung carcinoma 10.4 TP53 PGR
40 lung oat cell carcinoma 10.4 TP53 PTEN PIK3CA
41 breast juvenile papillomatosis 10.4 PIK3CA ERBB2
42 scirrhous adenocarcinoma 10.4 PGR ERBB2
43 lipid-rich breast carcinoma 10.4 PGR ERBB2
44 familial ovarian cancer 10.4 TP53 PTEN POLE
45 bone giant cell sarcoma 10.4 TP53 HRAS
46 liver adenomatosis 10.4 PGR CTNNB1
47 spitz nevus 10.4 TP53 LRRC56 HRAS
48 oncocytic breast carcinoma 10.4 PGR ERBB2
49 ovarian seromucinous carcinoma 10.4 TP53 PGR
50 apocrine adenosis of breast 10.4 TP53 PGR ERBB2

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma
Sources

Symptoms & Phenotypes for Uterine Carcinosarcoma

About this section

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.48 POLE
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.48 ERBB3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.48 U2AF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.48 EGFR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.48 POLE
6 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.48 U2AF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.48 KIT
8 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.48 U2AF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.48 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.48 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.48 ERBB2 POLE
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.48 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.48 POLE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.48 ERBB2 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.48 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.48 U2AF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.48 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.48 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.48 ERBB2 POLE
20 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.48 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.48 ERBB2 ERBB3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.48 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.48 ERBB2 POLE
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.48 EGFR ERBB2 ERBB3 KIT POLE U2AF1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.48 ERBB2 POLE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.48 U2AF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.48 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.48 EGFR POLE U2AF1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.48 KIT
30 Decreased viability GR00055-A-1 10.35 EGFR HRAS PIK3CA
31 Decreased viability GR00055-A-2 10.35 EGFR HRAS PIK3CA
32 Decreased viability GR00221-A-1 10.35 EGFR HRAS KIT PIK3CA PIK3R1
33 Decreased viability GR00221-A-2 10.35 HRAS PIK3CA
34 Decreased viability GR00221-A-3 10.35 HRAS PIK3R1
35 Decreased viability GR00221-A-4 10.35 EGFR PIK3CA
36 Decreased viability GR00301-A 10.35 KIT
37 Decreased viability GR00402-S-2 10.35 PIK3CA
38 Decreased substrate adherent cell growth GR00193-A-1 10.01 ERBB3 KIT
39 Decreased substrate adherent cell growth GR00193-A-2 10.01 EGFR ERBB3 FGFR2 KIT
40 Decreased substrate adherent cell growth GR00193-A-3 10.01 FGFR2
41 Decreased substrate adherent cell growth GR00193-A-4 10.01 KIT
42 Increased cell death in HCT116 cells GR00103-A-0 9.62 CTNNB1 FBXW7 PIK3CA PPP2R1A
43 Reduced mammosphere formation GR00396-S 9.23 EGFR ERBB3 HRAS PIK3R1 POLE PPP2R1A
44 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.96 CTNNB1
45 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.65 HRAS

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
2 homeostasis/metabolism MP:0005376 10.5 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
3 mortality/aging MP:0010768 10.49 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
4 endocrine/exocrine gland MP:0005379 10.47 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
5 growth/size/body region MP:0005378 10.46 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
6 integument MP:0010771 10.45 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
7 behavior/neurological MP:0005386 10.44 CTNNB1 ERBB2 ERBB3 FGFR2 HRAS KIT
8 embryo MP:0005380 10.44 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
9 cellular MP:0005384 10.43 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
10 immune system MP:0005387 10.43 CTNNB1 EGFR ERBB3 FBXW7 FGFR2 KIT
11 hematopoietic system MP:0005397 10.39 CTNNB1 EGFR FBXW7 FGFR2 KIT PGR
12 digestive/alimentary MP:0005381 10.38 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
13 neoplasm MP:0002006 10.38 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
14 muscle MP:0005369 10.31 CTNNB1 EGFR ERBB2 ERBB3 FGFR2 HRAS
15 nervous system MP:0003631 10.3 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
16 craniofacial MP:0005382 10.26 CTNNB1 EGFR ERBB2 FBXW7 FGFR2 HRAS
17 normal MP:0002873 10.25 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
18 liver/biliary system MP:0005370 10.18 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3R1
19 limbs/digits/tail MP:0005371 10.14 CTNNB1 EGFR ERBB2 FGFR2 KIT PGR
20 no phenotypic analysis MP:0003012 10.09 CTNNB1 EGFR FGFR2 HRAS KIT PGR
21 reproductive system MP:0005389 10.03 CTNNB1 EGFR ERBB2 FGFR2 KIT LRRC56
22 pigmentation MP:0001186 9.97 CTNNB1 EGFR ERBB3 FGFR2 KIT PTEN
23 renal/urinary system MP:0005367 9.92 CTNNB1 EGFR FGFR2 HRAS KIT PTEN
24 respiratory system MP:0005388 9.9 CTNNB1 EGFR ERBB2 ERBB3 FBXW7 FGFR2
25 skeleton MP:0005390 9.73 CTNNB1 EGFR ERBB2 FGFR2 HRAS KIT
26 vision/eye MP:0005391 9.36 CTNNB1 EGFR FBXW7 FGFR2 KIT PIK3CA
Sources

Drugs & Therapeutics for Uterine Carcinosarcoma

About this section

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Mesna Approved, Investigational Phase 3 3375-50-6 598
6
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
7
Cyproheptadine Approved Phase 3 129-03-3 2913
8
Liposomal doxorubicin Phase 3 31703
9 Antibiotics, Antitubercular Phase 3
10 Anti-Bacterial Agents Phase 3
11
Isophosphamide mustard Phase 3 100427
12 Alkylating Agents Phase 3
13 Gastrointestinal Agents Phase 3
14 Neurotransmitter Agents Phase 3
15 Anti-Allergic Agents Phase 3
16 Histamine Antagonists Phase 3
17 Dermatologic Agents Phase 3
18
Histamine Phosphate Phase 3 51-74-1 65513
19 Histamine H1 Antagonists Phase 3
20
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
23
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Gemcitabine Approved Phase 2 95058-81-4 60750
26
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
27
Iniparib Investigational Phase 2 160003-66-7
28
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
29 Angiogenesis Inhibitors Phase 2
30 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
31 Protein Kinase Inhibitors Phase 1, Phase 2
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
33 Anti-Infective Agents Phase 2
34 Immunosuppressive Agents Phase 2
35 Immunologic Factors Phase 2
36 Antimetabolites Phase 2
37 Antiviral Agents Phase 2
38 topoisomerase I inhibitors Phase 2
39
Paclitaxel Approved, Vet_approved 33069-62-4 36314
40
Carboplatin Approved 41575-94-4 10339178 498142 38904
41 Tubulin Modulators
42 Antimitotic Agents
43 Albumin-Bound Paclitaxel

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
2 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
4 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
5 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
7 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
8 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
9 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
10 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
11 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
12 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
13 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
14 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
15 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
16 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
17 Evaluation of Topotecan in the Treatment of Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Terminated NCT00003156 Phase 2 topotecan hydrochloride
18 A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma Terminated NCT01367301 paclitaxel;carboplatin

Search NIH Clinical Center for Uterine Carcinosarcoma

Sources

Genetic Tests for Uterine Carcinosarcoma

About this section
Sources

Anatomical Context for Uterine Carcinosarcoma

About this section

MalaCards organs/tissues related to Uterine Carcinosarcoma:

40
Breast, Uterus, Lung, Thyroid, Skin, Bone, Colon
Sources

Publications for Uterine Carcinosarcoma

About this section

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 414)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 6
26619011 2016
2
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 54 61
20189232 2010
3
COX-2 expression in uterine carcinosarcoma. 61 54
19900134 2010
4
Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. 54 61
17175012 2007
5
Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? 54 61
16445668 2006
6
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 54 61
15901136 2005
7
Cyclooxygenase-2 expression in uterine leiomyosarcomas. 54 61
15700850 2004
8
ERBB-2 gene overexpression and amplification in uterine sarcomas. 54 61
15581967 2004
9
Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. 61 54
14611676 2003
10
Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. 54 61
9311600 1997
11
COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. 61
33649798 2021
12
The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma. 61
33481373 2021
13
Imaging-guided percutaneous radiofrequency ablation of retroperitoneal metastatic disease in uterine carcinosarcoma. 61
33645390 2021
14
Yolk Sac Tumor Arising in Uterine Carcinosarcoma With Endometrioid and Serous Components: A Case Report With Immunohistochemical Analysis. 61
33770060 2021
15
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. 61
33183764 2021
16
Genetic characterization of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. 61
33527450 2021
17
Histomolecular features of high-grade endometrial cancers. 61
33104303 2021
18
Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases. 61
31855950 2021
19
Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen. 61
33753600 2021
20
Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. 61
33423127 2021
21
Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma. 61
33041218 2021
22
Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma? 61
33249415 2021
23
The effect of surgical approach on the outcomes and prognosis of high-risk histologic endometrioid carcinomas. 61
33633992 2021
24
Hypersensitivity Reaction to Carboplatin in Gynecologic Cancer: A Case Report and a Review of the Literature. 61
33678789 2021
25
Uterine Carcinosarcoma in a Young Female: Case Report and Literature Review. 61
33585128 2021
26
PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas. 61
33323859 2020
27
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2020
28
Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers. 61
33247676 2020
29
Cancer risks associated with the germline MITF(E318K) variant. 61
33051548 2020
30
The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. 61
33021035 2020
31
TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma. 61
32472441 2020
32
The Study of the Expression of CGB1 and CGB2 in Human Cancer Tissues. 61
32957442 2020
33
OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma. 61
32899312 2020
34
Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma. 61
32796408 2020
35
Executive summary of the American Radium Society® Appropriate Use Criteria for management of uterine carcinosarcoma. 61
32475772 2020
36
Targeting the TGFβ pathway in uterine carcinosarcoma. 61
33150300 2020
37
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. 61
32468052 2020
38
Renal Hemangioblastoma with Mixed Mullerian tumour of endometrium: A tale of two rare primary tumours. 61
32631354 2020
39
Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report. 61
32620662 2020
40
Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma. 61
32447295 2020
41
Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review. 61
31934920 2020
42
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
43
S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. 61
31857700 2020
44
Does chemotherapy or radiation benefit surgical stage I uterine carcinosarcoma patients? 61
31765639 2020
45
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. 61
32029291 2020
46
Molecular variations in uterine carcinosarcomas identify therapeutic opportunities. 61
32114514 2020
47
Adjuvant chemotherapy in endometrial cancer. 61
31950214 2020
48
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2020
49
Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms. 61
31789001 2020
50
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. 61
31765263 2020
Sources

Variations for Uterine Carcinosarcoma

About this section

ClinVar genetic disease variations for Uterine Carcinosarcoma:

6 (show top 50) (show all 174)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PPP2R1A NM_014225.6(PPP2R1A):c.536C>G (p.Pro179Arg) SNV Likely pathogenic 376504 rs786205228 GRCh37: 19:52715971-52715971
GRCh38: 19:52212718-52212718
2 ERBB3 NM_001982.3(ERBB3):c.889G>A (p.Asp297Asn) SNV Likely pathogenic 376409 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
3 ERBB3 NM_001982.3(ERBB3):c.889G>T (p.Asp297Tyr) SNV Likely pathogenic 376407 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
4 ERBB3 NM_001005915.1(ERBB3):c.310G>A (p.Val104Met) SNV Likely pathogenic 376410 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
5 ERBB3 NM_001005915.1(ERBB3):c.310G>T (p.Val104Leu) SNV Likely pathogenic 376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
6 PPP2R1A NM_014225.6(PPP2R1A):c.536C>T (p.Pro179Leu) SNV Likely pathogenic 190313 rs786205228 GRCh37: 19:52715971-52715971
GRCh38: 19:52212718-52212718
7 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala) SNV Likely pathogenic 376589 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
8 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys) SNV Likely pathogenic 12349 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
9 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly) SNV Likely pathogenic 376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
10 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
11 TP53 NM_000546.5(TP53):c.724T>G (p.Cys242Gly) SNV Likely pathogenic 376581 rs1057519982 GRCh37: 17:7577557-7577557
GRCh38: 17:7674239-7674239
12 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val) SNV Likely pathogenic 182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
13 TP53 NM_000546.5(TP53):c.536A>T (p.His179Leu) SNV Likely pathogenic 376608 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
14 TP53 NM_000546.5(TP53):c.745A>T (p.Arg249Trp) SNV Likely pathogenic 141881 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
15 TP53 NM_000546.5(TP53):c.577C>G (p.His193Asp) SNV Likely pathogenic 376613 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
16 TP53 NM_000546.5(TP53):c.725G>T (p.Cys242Phe) SNV Likely pathogenic 376578 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
17 TP53 NM_000546.5(TP53):c.535C>A (p.His179Asn) SNV Likely pathogenic 376609 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
18 TP53 NM_000546.5(TP53):c.746G>A (p.Arg249Lys) SNV Likely pathogenic 142241 rs587782329 GRCh37: 17:7577535-7577535
GRCh38: 17:7674217-7674217
19 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 GRCh37: 17:7578272-7578272
GRCh38: 17:7674954-7674954
20 TP53 NM_001276697.2(TP53):c.-27C>G SNV Likely pathogenic 376641 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
21 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely pathogenic 376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
22 TP53 NM_000546.5(TP53):c.487T>G (p.Tyr163Asp) SNV Likely pathogenic 187052 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
23 PPP2R1A NM_014225.6(PPP2R1A):c.548G>A (p.Arg183Gln) SNV Likely pathogenic 376506 rs1057519947 GRCh37: 19:52715983-52715983
GRCh38: 19:52212730-52212730
24 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
25 TP53 NM_000546.5(TP53):c.722C>A (p.Ser241Tyr) SNV Likely pathogenic 376663 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
26 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro) SNV Likely pathogenic 237954 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
27 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely pathogenic 376423 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
28 TP53 NM_000546.5(TP53):c.745A>G (p.Arg249Gly) SNV Likely pathogenic 376654 rs587782082 GRCh37: 17:7577536-7577536
GRCh38: 17:7674218-7674218
29 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro) SNV Likely pathogenic 142018 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
30 FBXW7 NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly) SNV Likely pathogenic 376422 rs747241612 GRCh37: 4:153247367-153247367
GRCh38: 4:152326215-152326215
31 ERBB2 NM_004448.3(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely pathogenic 375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
32 PIK3CA NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val) SNV Likely pathogenic 376479 rs1057519930 GRCh37: 3:178916930-178916930
GRCh38: 3:179199142-179199142
33 TP53 NM_000546.5(TP53):c.536A>C (p.His179Pro) SNV Likely pathogenic 376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
34 TP53 NM_000546.5(TP53):c.487T>C (p.Tyr163His) SNV Likely pathogenic 376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
35 TP53 NM_000546.5(TP53):c.647T>A (p.Val216Glu) SNV Likely pathogenic 376672 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
36 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Likely pathogenic 375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
37 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely pathogenic 376417 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
38 TP53 NM_000546.6(TP53):c.841G>C SNV Likely pathogenic 376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
39 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu) SNV Likely pathogenic 375899 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
40 TP53 NM_000546.5(TP53):c.535C>G (p.His179Asp) SNV Likely pathogenic 376610 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
41 TP53 NM_000546.5(TP53):c.838A>G (p.Arg280Gly) SNV Likely pathogenic 376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
42 TP53 NM_000546.5(TP53):c.578A>G (p.His193Arg) SNV Likely pathogenic 184979 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
43 TP53 NM_000546.5(TP53):c.647T>G (p.Val216Gly) SNV Likely pathogenic 376671 rs1057520004 GRCh37: 17:7578202-7578202
GRCh38: 17:7674884-7674884
44 TP53 NM_000546.5(TP53):c.843C>G (p.Asp281Glu) SNV Likely pathogenic 376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777
45 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys) SNV Likely pathogenic 376050 rs121913284 GRCh37: 3:178921553-178921553
GRCh38: 3:179203765-179203765
46 HRAS , LRRC56 NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
47 TP53 NM_000546.5(TP53):c.716A>C (p.Asn239Thr) SNV Likely pathogenic 376638 rs1057519999 GRCh37: 17:7577565-7577565
GRCh38: 17:7674247-7674247
48 PPP2R1A NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp) SNV Likely pathogenic 376505 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
49 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely pathogenic 217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
50 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
Sources

Expression for Uterine Carcinosarcoma

About this section
Search GEO for disease gene expression data for Uterine Carcinosarcoma.
Sources

Pathways for Uterine Carcinosarcoma

About this section

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 156)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.29 TP53 RACGAP1 PTEN PPP2R1A PIK3R1 PIK3CA
2
Innate Immune System 65
Show member pathways
 14.13 TP53 RACGAP1 PTGS2 PTEN PPP2R1A PIK3R1
3
ERK Signaling 63
Show member pathways
 13.93 TP53 SNAI2 PTGS2 PTEN PPP2R1A PIK3R1
4
HIV Life Cycle 65
Show member pathways
 13.84 PPP2R1A PIK3R1 PIK3CA KIT HRAS FGFR2
5
GPCR Pathway 63
Show member pathways
 13.82 TP53 PTGS2 PPP2R1A PIK3R1 KIT HRAS
6
PEDF Induced Signaling 63
Show member pathways
 13.81 TP53 PTGS2 PPP2R1A PIK3R1 KIT HRAS
7
Activation of cAMP-Dependent PKA 63
Show member pathways
 13.67 PIK3R1 KIT HRAS FGFR2 ERBB3 ERBB2
8
TGF-Beta Pathway 63
Show member pathways
 13.67 TP53 PPP2R1A PIK3R1 PIK3CA KIT HRAS
9
Developmental Biology 65
Show member pathways
 13.63 PPP2R1A PIK3R1 PIK3CA KIT HRAS FGFR2
10
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.56 TP53 RACGAP1 PTEN PPP2R1A PIK3R1 PIK3CA
11
Akt Signaling 63
Show member pathways
 13.54 TP53 PTEN PPP2R1A PIK3R1 KIT HRAS
12
Cytokine Signaling in Immune system 65
Show member pathways
 13.49 TP53 PTGS2 PPP2R1A PIK3R1 PIK3CA KIT
13
CREB Pathway 63
Show member pathways
 13.46 PTEN PIK3R1 KIT HRAS FGFR2 ERBB3
14
PAK Pathway 63
Show member pathways
 13.44 SNAI2 PTEN PIK3R1 KIT HRAS FGFR2
15
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.41 PPP2R1A PIK3R1 KIT HRAS FGFR2 ERBB3
16
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.33 TP53 PPP2R1A PIK3R1 PIK3CA HRAS EGFR
17
PI3K/AKT activation 65
Show member pathways
 13.25 TP53 PTEN PPP2R1A PIK3R1 PIK3CA KIT
18
TNFR1 Pathway 63
Show member pathways
 13.21 TP53 PTEN PIK3R1 PIK3CA HRAS EGFR
19
Phospholipase-C Pathway 63
Show member pathways
 13.2 TP53 PTEN PIK3R1 KIT HRAS FGFR2
20
p70S6K Signaling 63
Show member pathways
 13.18 PTGS2 PPP2R1A PIK3R1 KIT HRAS FGFR2
21
Human cytomegalovirus infection 36
Show member pathways
 13.08 TP53 PTGS2 PIK3R1 PIK3CA HRAS EGFR
22
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 13.05 KIT FGFR2 ERBB3 ERBB2 EGFR
23
Focal Adhesion 36 1
Show member pathways
 13.04 PTGS2 PTEN PIK3R1 PIK3CA HRAS ERBB2
24
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.01 PTEN PIK3R1 PIK3CA HRAS FGFR2 ERBB3
25
ErbB4 Pathway 63
Show member pathways
 12.97 TP53 PTEN PIK3R1 HRAS ERBB3 ERBB2
26
Development Angiotensin activation of ERK 23
Show member pathways
 12.96 PIK3R1 PIK3CA KIT HRAS EGFR
27
Endometrial cancer 36
Show member pathways
 12.95 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
28
MAPK signaling pathway 36 1
12.91 TP53 KIT HRAS FGFR2 ERBB3 ERBB2
29
Ras signaling pathway 36
Show member pathways
 12.88 PIK3R1 PIK3CA KIT HRAS FGFR2 EGFR
30
Development HGF signaling pathway 23
Show member pathways
 12.87 TP53 PTGS2 PTEN PIK3R1 PIK3CA HRAS
31
Glioma 36
Show member pathways
 12.83 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
32
4-1BB Pathway 63
Show member pathways
 12.79 TP53 PPP2R1A PIK3R1 HRAS EGFR
33
Pathways in cancer 36
12.79 TP53 PTGS2 PTEN PIK3R1 PIK3CA KIT
34
Regulation of actin cytoskeleton 36 1
12.77 PIK3R1 PIK3CA HRAS FGFR2 EGFR
35
Immune response IL-23 signaling pathway 23
Show member pathways
 12.74 TP53 PIK3R1 PIK3CA HRAS ERBB2 EGFR
36
T cell receptor signaling pathway 36
Show member pathways
 12.73 PTEN PIK3R1 PIK3CA HRAS EGFR
37
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.72 PTGS2 PTEN PIK3R1 PIK3CA HRAS
38
Negative regulation of FGFR1 signaling 65
Show member pathways
 12.71 PPP2R1A PIK3R1 PIK3CA HRAS FGFR2
39
Development Dopamine D2 receptor transactivation of EGFR 23
Show member pathways
 12.7 PPP2R1A PIK3R1 PIK3CA HRAS EGFR
40
Gastric cancer 36
Show member pathways
 12.66 TP53 PTEN PIK3R1 PIK3CA PGR KIT
41
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.63 TP53 PPP2R1A PIK3R1 PIK3CA HRAS
42
Prolactin Signaling Pathway 1 36
Show member pathways
 12.62 PTEN PIK3R1 PIK3CA HRAS ERBB2
43
MicroRNAs in cancer 36
12.62 TP53 PTGS2 PTEN PIK3R1 PIK3CA HRAS
44
PI3K-Akt signaling pathway 36
Show member pathways
 12.6 TP53 PTGS2 PTEN PPP2R1A PIK3R1 PIK3CA
45
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.58 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
46
Shigellosis 36
12.55 U2AF1 TP53 PIK3R1 PIK3CA EGFR
47
Phospholipase D signaling pathway 36
Show member pathways
 12.55 PIK3R1 PIK3CA KIT HRAS EGFR
48
ErbB signaling pathway 36 1
Show member pathways
 12.55 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
49
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.54 PTGS2 PIK3R1 PIK3CA HRAS CTNNB1
50
Development IGF-1 receptor signaling 23
Show member pathways
 12.54 TP53 PTEN PIK3R1 PIK3CA HRAS
Sources

GO Terms for Uterine Carcinosarcoma

About this section

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.27 RACGAP1 PTEN PPP2R1A POLE PIK3R1 PIK3CA
2 cytoplasm GO:0005737 10.16 TP53 SNAI2 RACGAP1 PTGS2 PTEN PPP2R1A
3 protein-containing complex GO:0032991 9.91 TP53 PTGS2 PIK3R1 FBXW7 EGFR CTNNB1
4 nucleus GO:0005634 9.86 U2AF1 TP53 SNAI2 RACGAP1 PTGS2 PTEN
5 basolateral plasma membrane GO:0016323 9.8 ERBB3 ERBB2 EGFR CTNNB1
6 perinuclear region of cytoplasm GO:0048471 9.7 PIK3R1 PIK3CA HRAS FBXW7 ERBB2 EGFR
7 lateral plasma membrane GO:0016328 9.65 PPP2R1A ERBB3 CTNNB1
8 basal plasma membrane GO:0009925 9.58 ERBB3 ERBB2 EGFR
9 phosphatidylinositol 3-kinase complex, class IA GO:0005943 9.37 PIK3R1 PIK3CA
10 ERBB3:ERBB2 complex GO:0038143 9.32 ERBB3 ERBB2
11 receptor complex GO:0043235 9.02 KIT FGFR2 ERBB3 ERBB2 EGFR

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.23 SNAI2 RACGAP1 KIT FGFR2 ERBB3 ERBB2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TP53 PIK3R1 PGR HRAS FGFR2 EGFR
3 phosphorylation GO:0016310 10.15 PIK3CA KIT FGFR2 ERBB3 ERBB2 EGFR
4 negative regulation of apoptotic process GO:0043066 10.11 TP53 PTGS2 PTEN PIK3R1 EGFR CTNNB1
5 negative regulation of cell proliferation GO:0008285 10.09 TP53 PTGS2 PTEN HRAS CTNNB1
6 protein phosphorylation GO:0006468 10.09 PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
7 negative regulation of gene expression GO:0010629 10.05 TP53 PGR HRAS FBXW7 CTNNB1
8 cytokine-mediated signaling pathway GO:0019221 10.04 TP53 PTGS2 PIK3R1 PIK3CA KIT
9 positive regulation of gene expression GO:0010628 10.04 TP53 PTEN KIT HRAS ERBB3 ERBB2
10 positive regulation of cell migration GO:0030335 10.02 SNAI2 PIK3R1 KIT HRAS EGFR
11 heart development GO:0007507 10 TP53 PTEN ERBB3 ERBB2 CTNNB1
12 protein stabilization GO:0050821 9.98 TP53 PTEN PIK3R1 FBXW7
13 protein autophosphorylation GO:0046777 9.97 KIT FGFR2 ERBB2 EGFR
14 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 PTEN HRAS FGFR2 FBXW7 EGFR
15 regulation of cell proliferation GO:0042127 9.97 TP53 PTGS2 KIT ERBB3 CTNNB1
16 MAPK cascade GO:0000165 9.93 KIT HRAS FGFR2 ERBB3 ERBB2 EGFR
17 response to estradiol GO:0032355 9.92 PTGS2 PTEN EGFR CTNNB1
18 wound healing GO:0042060 9.91 FGFR2 ERBB3 ERBB2 EGFR
19 positive regulation of cell proliferation GO:0008284 9.91 PTGS2 PTEN KIT HRAS FGFR2 ERBB3
20 lung development GO:0030324 9.89 FGFR2 FBXW7 EGFR CTNNB1
21 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 PIK3R1 PIK3CA KIT ERBB3
22 peptidyl-tyrosine phosphorylation GO:0018108 9.88 KIT FGFR2 ERBB3 ERBB2 EGFR
23 phosphatidylinositol biosynthetic process GO:0006661 9.87 PTEN PIK3R1 PIK3CA
24 cellular response to growth factor stimulus GO:0071363 9.87 ERBB2 EGFR CTNNB1
25 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 PTGS2 FGFR2 EGFR
26 epidermal growth factor receptor signaling pathway GO:0007173 9.84 PIK3R1 PIK3CA EGFR
27 positive regulation of epithelial cell proliferation GO:0050679 9.84 HRAS FGFR2 ERBB2 EGFR
28 cellular response to epidermal growth factor stimulus GO:0071364 9.83 SNAI2 ERBB2 EGFR
29 epithelial to mesenchymal transition GO:0001837 9.83 SNAI2 FGFR2 CTNNB1
30 positive regulation of MAP kinase activity GO:0043406 9.83 KIT HRAS ERBB2 EGFR
31 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 KIT FGFR2 ERBB3 ERBB2 EGFR
32 regulation of cell motility GO:2000145 9.81 ERBB3 ERBB2 EGFR
33 cellular response to UV GO:0034644 9.81 TP53 PTGS2 PIK3R1 FBXW7
34 regulation of ERK1 and ERK2 cascade GO:0070372 9.8 FGFR2 ERBB2 EGFR
35 positive regulation of MAPK cascade GO:0043410 9.8 KIT HRAS FGFR2 ERBB2 CTNNB1
36 vasculature development GO:0001944 9.79 PIK3CA FBXW7 CTNNB1
37 regulation of osteoblast differentiation GO:0045667 9.73 SNAI2 FGFR2 CTNNB1
38 positive regulation of kinase activity GO:0033674 9.72 KIT FGFR2 ERBB3 ERBB2 EGFR
39 tongue development GO:0043586 9.7 KIT EGFR
40 negative regulation of ERBB signaling pathway GO:1901185 9.68 ERBB2 EGFR
41 lung-associated mesenchyme development GO:0060484 9.67 FGFR2 CTNNB1
42 embryonic organ development GO:0048568 9.67 TP53 POLE FGFR2 CTNNB1
43 mesenchymal cell proliferation involved in lung development GO:0060916 9.64 FGFR2 CTNNB1
44 phosphatidylinositol 3-kinase signaling GO:0014065 9.55 PTEN PIK3R1 PIK3CA ERBB3 ERBB2
45 positive regulation of protein kinase B signaling GO:0051897 9.5 PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
46 ERBB2 signaling pathway GO:0038128 9.02 PIK3R1 PIK3CA ERBB3 ERBB2 EGFR

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.37 U2AF1 TP53 SNAI2 RACGAP1 PTGS2 PTEN
2 nucleotide binding GO:0000166 10.1 POLE PIK3CA KIT HRAS FGFR2 ERBB3
3 identical protein binding GO:0042802 10.06 TP53 PTEN PGR FGFR2 FBXW7 ERBB3
4 kinase activity GO:0016301 9.91 PIK3CA KIT FGFR2 ERBB3 ERBB2 EGFR
5 protein kinase binding GO:0019901 9.88 TP53 RACGAP1 PTEN EGFR CTNNB1
6 protein heterodimerization activity GO:0046982 9.8 TP53 PPP2R1A PIK3R1 ERBB3 ERBB2
7 enzyme binding GO:0019899 9.8 TP53 PTGS2 PTEN PGR EGFR CTNNB1
8 protein tyrosine kinase activity GO:0004713 9.65 KIT FGFR2 ERBB3 ERBB2 EGFR
9 insulin receptor substrate binding GO:0043560 9.51 PIK3R1 PIK3CA
10 protein phosphatase binding GO:0019903 9.35 TP53 PIK3R1 ERBB2 EGFR CTNNB1
11 ErbB-3 class receptor binding GO:0043125 9.33 PIK3R1 ERBB3 ERBB2
12 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 KIT FGFR2 ERBB3 ERBB2 EGFR
Sources

Sources for Uterine Carcinosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....